

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: CAMPOCHIARO et al.  
Appl. No.: 10/526,127  
Conf. No.: 2577  
Filed: 6 November 2006  
Title: **OCULAR GENE THERAPY**  
Art Unit: 1633  
Examiner: Long, Scott  
Docket No.: 010804-22690600

**MAIL STOP APPEAL BRIEFS-PATENTS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Submitted concurrently herewith is a Form PTO/SB/08a.

All of the documents cited on the accompanying PTO/SB/08a, with the exception of the U.S. Patents and U.S. Patent Application Publications, were cited first in a communication in the patent office of a foreign counterpart of the instant application not more than three months prior to the instant Information Disclosure Statement. All of the U.S. Patents and U.S. Patent Application Publications cited on the accompanying Form PTO/SB/08a are just U.S. counterparts of some of the cited Foreign Patent Documents.

As noted in the attached copy of the Opposition, fourteen documents were cited therein.

D1 is U.S. Ser. No. 60/406,470, the priority document of the instant application.

D2 is Takahashi et al., which is of record and was considered by the Examiner, as noted in the acknowledgment PTO/SB/08a attached to the Office Action mailed 14 December 2009.

D3 is WO 02/067971. Published U.S. counterpart, U.S. App. Pub. No. 20020183253, is of record and was considered by the Examiner, as noted in the acknowledgment PTO/SB/08a attached to the Office Action mailed 14 December 2009. U.S. App. Pub. No. 20020183253 is abandoned in favor of continuation, U.S. App. Pub. No. 20100286253.

D4 is WO 03/86178 of Soker et al. U.S. counterparts, U.S. App. Pub. Nos. 20050203013 and 20050112063, that claim benefit to the PCT application and to the priority application of WO 03/86178, are listed in the attached form PTO/SB/08a. Both U.S. App. Pub. Nos. 20050203013 and 20050112063 are abandoned.

D5 is Rasmussen et al. and is relied on to ground three obviousness rejections on appeal.

D6 is Mori et al., which was relied on by the Examiner to ground novelty and obviousness rejections in the Office Action of 2 May 2009. Those rejections were overcome.

D7 is WO 02/30982 of Sim et al. The U.S. counterpart, U.S. App. Pub. No. 20020086007, is abandoned and is listed in the attached form PTO/SB/08a.

D8 is U.S. Pat. No. 6,267,954, which is of record and was considered by the Examiner, as noted in the acknowledgment PTO/SB/08a attached to the Office Action mailed 2 March 2009.

D9 is Kanski.

D10 is Bressler et al., a reference cited in D5.

D11 is Ferris et al. (Arch Ophthalmol), another reference cited in D5.

D12 is a second Ferris et al. reference (NEJM), yet another reference cited in D5.

D13 is WO 00/38714 of Adamis. U.S. counterparts, U.S. App. Pub. Nos. 20040028648 (abandoned), 20080019977 (abandoned) and 20100203061 (pending), and U.S. Pat. Nos. 6,670,321 and 6,524,581, that claim benefit to the priority applications of WO 03/86178, are listed in the attached Form PTO/SB/08a.

D14 is Kim et al.

Respectfully submitted,

MDIP LLC

BY /Dean Nakamura/  
Dean H. Nakamura  
Reg. No. 33,981  
P.O. Box 2630  
Montgomery Village, MD  
20886-2630  
Phone: (202) 412-6986

Dated: 17 February 2011